<div id="readability-page-1"><div><ul> <li>Earlier this week, UBS Group upgraded Corcept Therapeutics following increased confidence in Lifyoril, its investigational ovarian cancer therapy, while a senior executive reported bona fide gifts of company shares to family accounts. </li> <li>This combination of heightened optimism around an additional oncology asset and insider estate planning activity offers a fresh lens on Corcept’s evolving profile. </li> <li>We’ll now examine how UBS’s increased confidence in Lifyoril’s regulatory outlook may influence Corcept Therapeutics’ broader investment narrative. </li> </ul><p>AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</p><h2>Corcept Therapeutics Investment Narrative Recap</h2><p>To own Corcept today, you need to believe that Korlym’s erosion can be offset by new cortisol modulators and oncology uses for relacorilant, with Lifyoril in ovarian cancer now a central part of that story. UBS’s upgrade, tied to confidence in Lifyoril’s regulatory path, potentially reinforces that near term catalyst. At the same time, recent earnings volatility and the overhang from Korlym generics still look like the most immediate business risks, which this week’s news does not remove.</p> <p>The UBS call is most relevant here because it explicitly links a higher target price to expectations around Lifyoril’s approval and uptake in platinum resistant ovarian cancer. That sits alongside recent ROSELLA data and regulatory progress, which together frame how much relacorilant could reduce Corcept’s dependence on Korlym if approvals translate into real world use. For investors, this creates a clear focal point around upcoming oncology updates and how quickly the new indication can contribute.</p> <p>Yet against this growing optimism, investors should also be aware of the unresolved patent appeal with Teva and what a weaker outcome could mean for Korlym...</p> <p>Read the full narrative on Corcept Therapeutics (it's free!)</p><p>Corcept Therapeutics' narrative projects $1.6 billion revenue and $607.0 million earnings by 2029. This requires 27.5% yearly revenue growth and an earnings increase of about $560 million from $46.7 million today.</p><p>Uncover how Corcept Therapeutics' forecasts yield a $73.40 fair value, a 30% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9debd0be-0e12-4a5b-bb89-86d4785ce898/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9debd0be-0e12-4a5b-bb89-86d4785ce898/chart/quote-price"/><figcaption>CORT 1-Year Stock Price Chart</figcaption></figure> <p>While consensus focuses on Korlym pressure and relacorilant execution, the most bullish analysts were once modeling revenue reaching about US$1.9 billion and earnings around US$708 million, showing how differently you can weigh today’s Lifyoril news against the risk that multiple late stage programs could still face delays or setbacks.</p><p>Explore 5 other fair value estimates on Corcept Therapeutics - why the stock might be worth over 2x more than the current price!</p><h2>Decide For Yourself</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Corcept Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Corcept Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Corcept Therapeutics' overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li><li>Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.</li><li>Find 51 companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

CORT

LABU

SBIO

<p>UBS Group upgraded Corcept Therapeutics, citing increased confidence in its ovarian cancer therapy, Lifyoril. This upgrade, alongside insider share gifting, highlights Corcept's evolving profile. While optimism grows around Lifyoril's regulatory outlook, risks remain from Korlym generics and earnings volatility. Analysts project significant revenue growth, with a fair value estimate of $73.40, indicating a potential 30% upside from current prices. Investors should consider both the positive developments and ongoing challenges as they evaluate Corcept's investment narrative.</p>

Simplywall

Corcept Therap

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

UBS Group AG

Teva Pharmaceutical Industries

NVIDIA

Microsoft

NVIDIA Corporation

Does Corcept Therapeutics' (CORT) UBS Upgrade and Insider Gifting Reframe Its Oncology Ambitions?